Development asset linked to Pierre Fabre Medicament in public FDA and regional records.
pharma · Breast Cancer · Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease
Pierre Fabre Medicament
Pierre Fabre Medicament drug portfolio — 13 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
LAVAUR, FR HQ
176 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- LAVAUR, FR
- Employees
- 176
- Programs
- 8
- Drugs
- 13
- Patents
- 0
Pierre Fabre Medicament pipeline
Portfolio lens on 13 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Pierre Fabre Medicament drug portfolio — 13 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Pierre Fabre Medicament in public FDA and regional records.
-
Development asset linked to Pierre Fabre Medicament in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Pierre Fabre Medicament in public FDA and regional records.
-
Development asset linked to Pierre Fabre Medicament in public FDA and regional records.
-
Development asset linked to Pierre Fabre Medicament in public FDA and regional records.
-
rituximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
Development asset linked to Pierre Fabre Medicament in public FDA and regional records.
-
Development asset linked to Pierre Fabre Medicament in public FDA and regional records. Mechanism: The T-cell receptor recognises an EBV peptide in complex with a specific HLA molecule on the surface of target cells to exert cytotoxic activity.
- Mechanism
- The T-cell receptor recognises an EBV peptide in complex with a specific HLA molecule on the surface of target cells to exert cytotoxic activity
-
Development asset linked to Pierre Fabre Medicament in public FDA and regional records.
-
Development asset linked to Pierre Fabre Medicament in public FDA and regional records.
-
vinflunine
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Pierre Fabre Medicament's portfolio. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor